Clinical Trial

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

Study acronym: EPURE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the operating room and administered for 4 days during the post-operative period) on graft function evaluated by the measurement of glomerular filtration rate at 3 months - variable strongly associated with long-term graft survival.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2015-07-06; most recent amendment 2023-06-16.
Status change: Recruiting → Active, Not Recruiting 2022-11-09
Status change: Not Yet Recruiting → Recruiting 2017-06-21
Trial Details
NCT Number NCT02490904
Lead Sponsor Central Hospital, Nancy, France
Conditions End-stage Renal Disease
Enrollment 132 participants
Start Date 2016-10-19
Primary Completion 2021-11-09 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2023-06-18